

# Gareth P Gregory

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4392355/publications.pdf>

Version: 2024-02-01

43  
papers

1,505  
citations

430874

18  
h-index

330143

37  
g-index

45  
all docs

45  
docs citations

45  
times ranked

2817  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. <i>Nature Communications</i> , 2018, 9, 5341.	12.8	356
2	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019, 134, 6-6.	1.4	152
3	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. <i>Cell</i> , 2021, 184, 3143-3162.e32.	28.9	103
4	The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. <i>Cancer Research</i> , 2016, 76, 1158-1169.	0.9	100
5	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. <i>Science Advances</i> , 2020, 6, .	10.3	79
6	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. <i>Molecular Cell</i> , 2021, 81, 2183-2200.e13.	9.7	59
7	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2030-2041.	4.1	57
8	Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. <i>Neuro-Oncology</i> , 2013, 15, 1068-1073.	1.2	54
9	A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. <i>Leukemia</i> , 2020, 34, 1646-1657.	7.2	54
10	Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. <i>Blood</i> , 2020, 136, 42-44.	1.4	44
11	AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. <i>Clinical Cancer Research</i> , 2020, 26, 6535-6549.	7.0	42
12	Bcr loss perturbs myeloid differentiation and promotes leukaemogenesis. <i>Nature Communications</i> , 2019, 10, 1347.	12.8	41
13	Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. <i>Journal of Personalized Medicine</i> , 2021, 11, 355.	2.5	41
14	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 667-679.	0.8	37
15	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021, 11, 1582-1599.	9.4	35
16	Genomic characterisation of $\frac{1}{4}$ -Myc mouse lymphomas identifies Bcr as a Myc co-operative tumour-suppressor gene. <i>Nature Communications</i> , 2017, 8, 14581.	12.8	33
17	Failure of eculizumab to correct paroxysmal cold hemoglobinuria. <i>Annals of Hematology</i> , 2011, 90, 989-990.	1.8	27
18	Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. <i>British Journal of Haematology</i> , 2019, 187, 174-184.	2.5	23

#	ARTICLE	IF	CITATIONS
19	Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. <i>Blood</i> , 2021, 137, 2947-2957.	1.4	19
20	Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. <i>Annals of Hematology</i> , 2016, 95, 667-668.	1.8	18
21	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. <i>Blood</i> , 2021, 138, 132-132.	1.4	15
22	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. <i>Blood</i> , 2021, 138, 181-181.	1.4	14
23	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. <i>Blood Advances</i> , 2022, 6, 1232-1242.	5.2	14
24	<sc>COVID</sc>â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.8	12
25	Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. <i>Current Opinion in Hematology</i> , 2014, 21, 297-308.	2.5	8
26	Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 997-1003.	2.3	8
27	Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004994.	1.2	7
28	An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies. <i>Blood</i> , 2019, 134, 1594-1594.	1.4	7
29	Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies. <i>Blood</i> , 2019, 134, 1548-1548.	1.4	7
30	Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia. <i>Annals of Hematology</i> , 2020, 99, 2455-2456.	1.8	6
31	A consensus statement on the use of biosimilar medicines in hematology in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 211-221.	1.1	6
32	Cold agglutinin disease complicated by acrocyanosis and necrosis. <i>Annals of Hematology</i> , 2017, 96, 509-510.	1.8	5
33	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 112-117.	1.3	5
34	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. <i>Targeted Oncology</i> , 2021, 16, 761-771.	3.6	5
35	Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance. <i>Blood</i> , 2021, 138, 882-882.	1.4	3
36	AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 567-568.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 739-741.	2.5	1
38	Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH. <i>Leukemia and Lymphoma</i> , 2021, 62, 3060-3062.	1.3	1
39	Salvage radiotherapy associates with durable response for a subset of patients with limited stage refractory DLBCL. <i>Blood Advances</i> , 2021, 5, 5112-5115.	5.2	1
40	Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience. <i>Internal Medicine Journal</i> , 2021, 51, 1825-1834.	0.8	0
41	3002 “REPROGRAMMING OF SERINE METABOLISM IS A METABOLIC VULNERABILITY IN FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTANT ACUTE MYELOID LEUKAEMIA. <i>Experimental Hematology</i> , 2020, 88, S37-S38.	0.4	0
42	Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA). <i>Blood</i> , 2021, 138, 2532-2532.	1.4	0
43	Diagnosis and management of primary central nervous system lymphoma: a Consensus Practice Statement from the Australasian Lymphoma Alliance. <i>Internal Medicine Journal</i> , 2021, , .	0.8	0